It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2020
  5. Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylating agent (HMA) therapy for MDS and CMML

July 8, 2020

Otsuka Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylating agent (HMA) therapy for MDS and CMML

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) and Health Canada have approved INQOVI® (decitabine and cedazuridine) tablets for intermediate and high-risk MDS (myelodysplastic syndromes) and CMML (chronic myelomonocytic leukemia), two blood malignancies.

INQOVI is the first and only orally administered hypomethylating agent approved in the U.S. and Canada for the treatment of MDS and CMML.

Approval in the U.S. and Canada was based on data from the ASCERTAIN phase three study and supporting phase one and two clinical studies. The ASCERTAIN phase three study evaluated the five-day, decitabine exposure equivalence between oral INQOVI and intravenous decitabine. The safety and efficacy of INQOVI was also assessed in the clinical studies.

The announcement is also being issued by Otsuka's California-based subsidiary Astex Pharmaceuticals, Inc.; and by Taiho Pharmaceutical Co., Ltd. and its North American subsidiaries. The three companies are all part of the Otsuka group of companies.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases